Our top pick for
US stocks

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Sienna Cancer Diagnostics is a diagnostics & research business based in Australia. Sienna Cancer Diagnostics shares (SDX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Sienna Cancer Diagnostics has a trailing 12-month revenue of around $999,521. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
52-week range | $0 - $0 |
---|---|
50-day moving average | $0.0692 |
200-day moving average | $0.0519 |
Target price | $0.29 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.011 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Revenue TTM | $999,521 |
---|---|
Gross profit TTM | $989,610 |
Return on assets TTM | -20.32% |
Return on equity TTM | -35.97% |
Profit margin | 0% |
Book value | 0.026 |
Market capitalisation | $27.7 million |
TTM: trailing 12 months
We're not expecting Sienna Cancer Diagnostics to pay a dividend over the next 12 months.
Over the last 12 months, Sienna Cancer Diagnostics 's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Sienna Cancer Diagnostics 's is 3.007. This would suggest that Sienna Cancer Diagnostics 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Sienna Cancer Diagnostics Limited, a medical technology company, identifies, develops, and commercializes cancer-related in-vitro diagnostic tests for use in pathology laboratories worldwide. The company offers SCD-A7, an anti-human telomerase reverse transcriptase antibody for the detection of the biomarker for cancer. It also provides SIEN-NET technology, a sample preparation platform to enhance the performance of liquid biopsy diagnostic assays. The company has a research collaboration agreement with Minomic International Ltd to develop a proprietary test for the early detection of pancreatic cancer. The company was formerly known as Sienna Capital Ltd and changed its name to Sienna Cancer Diagnostics Limited in 2006. Sienna Cancer Diagnostics Limited was founded in 2002 and is headquartered in Scoresby, Australia.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.
Steps to owning and managing The Lottery Corporation shares.
Steps to owning and managing Endeavour Group shares.